PAOLINI, ERIKA
PAOLINI, ERIKA
Dipartimento di Scienze Farmacologiche e Biomolecolari Rodolfo Paoletti
Single Cell Analysis Reveals the Presence of Novel Intermediate Cells in Both Mice and Patients With Severe MASLD
2026 M. Meroni, P. Pelucchi, E. Paolini, M. Longo, A. Sula, M. Battistin, A. Chiodi, D. Mattinzoli, M. Ikehata, E. Trombetta, D. Dondossola, A. Mezzelani, G.M. Tartaglia, G. Castellano, A.L. Fracanzani, F. Peyvandi, S. Gatti, E. Mosca, P. Dongiovanni
The KLB rs12152703 variant confers protection against hepatic inflammation in patients with MASLD by boosting Klotho-beta expression
2026 M. Meroni, N. Panera, E. Paolini, M. Longo, F. Tiano, C. De Stefanis, V. D'Oria, A. Mosca, S. Badiali, M. Maggioni, E. Mosca, A.L. Fracanzani, A. Alisi, P. Dongiovanni
A defective circulating mitochondrial bioenergetics profile reflects the hepatic one and outlines genetic MASLD
2025 E. Paolini, M. Longo, M. Meroni, P. Podini, M. Maggioni, A. Quattrini, A.L. Fracanzani, P. Dongiovanni
Artificial intelligence as a ploy to delve into the intricate link between genetics and mitochondria in patients with MASLD
2025 M. Longo, E. Paolini, M. Meroni, M. Ripolone, L. Napoli, F. Gentile, A. Cespiati, E. Trombetta, R. Lombardi, M. Maggioni, A. Alisi, L. Miele, A. Liguori, G. Soardo, A. Gasbarrini, M. Moggio, A.L. Fracanzani, P. Dongiovanni
Exploring multiorgan mitochondrial dysfunction in the switch toward progressive MASLD in AMLN mice
2025 M. Meroni, E. Paolini, M. Longo, M. Battistin, D. Dondossola, M. Ripolone, L. Napoli, E. Mosca, S. Corti, P. Dongiovanni
Next Generation Sequencing Allows Identification of a Novel Mutation in the TfR2 Gene and Outperforms the Conventional Diagnostic Techniques
2025 M. Longo, E. Paolini, M. Meroni, F. Cinque, C. Bertelli, G. Pisano, M. Maggioni, A.L. Fracanzani, R. Lombardi, P. Dongiovanni
THE MBOAT7 AND TM6SF2 GENETIC REPLENISHMENT RESCUES THE MITOCHONDRIAL DYNAMICS IN IN VITRO NAFLD MODELS AND OPENS A SPYHOLE TOWARDS MITOCHONDRIAL BIOMARKERS FOR NON-INVASIVE NAFLD DIAGNOSIS
2024 E. Paolini
The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value
2023 E. Paolini, M. Longo, M. Meroni, G. Tria, A. Cespiati, R. Lombardi, S. Badiali, M. Maggioni, A.L. Fracanzani, P. Dongiovanni
Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution
2022 M. Longo, E. Paolini, M. Meroni, P. Dongiovanni
TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
2022 M. Longo, M. Meroni, E. Paolini, V. Erconi, F. Carli, F.R. Fortunato, D. Ronchi, R. Piciotti, S. Sabatini, C. Macchi, A. Alisi, L. Miele, G. Soardo, G.P. Comi, L.V.C. Valenti, M. Ruscica, A.L. Fracanzani, A. Gastaldelli, P. Dongiovanni
MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients
2022 M. Meroni, M. Longo, E. Paolini, R. Lombardi, R. Piciotti, P. Francione, S. Badiali, M. Maggioni, A.L. Fracanzani, P. Dongiovanni
Recreating gut-liver axis during NAFLD onset by using a Caco-2/HepG2 co-culture system
2022 M. Meroni, E. Paolini, M. Longo, R. Piciotti, G. Tria, S. Fargion, A. Ludovica Fracanzani, P. Dongiovanni
Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia
2022 M. Meroni, M. Longo, E. Paolini, G. Tria, M. Ripolone, L. Napoli, M. Moggio, A.L. Fracanzani, P. Dongiovanni
$\upalpha$-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study [alpha-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study]
2021 M. Longo, E. Paolini, M. Meroni, L. Duca, I. Motta, A.L. Fracanzani, E. Di Pierro, P. Dongiovanni
The α-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study
2021 M. Longo, E. Paolini, M. Meroni, L. Duca, I. Motta, A.L. Fracanzani, E. DI PIERRO, P. Dongiovanni
NAFLD or MAFLD diagnoses and cardiovascular diseases: from epidemiology to drug approaches
2021 P. Dongiovanni, E. Paolini, A. Corsini, C.R. Sirtori, M. Ruscica
Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
2021 M. Meroni, M. Longo, R. Lombardi, E. Paolini, C. Macchi, A. Corsini, C.R. Sirtori, A.L. Fracanzani, M. Ruscica, P. Dongiovanni
Remodeling of mitochondrial plasticity: The key switch from NAFLD/Nash to HCC
2021 M. Longo, E. Paolini, M. Meroni, P. Dongiovanni
Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?
2021 M. Longo, M. Meroni, E. Paolini, C. Macchi, P. Dongiovanni
The rs599839 a>g variant disentangles cardiovascular risk and hepatocellular carcinoma in nafld patients
2021 M. Meroni, M. Longo, E. Paolini, A. Alisi, L. Miele, E.R. De Caro, G. Pisano, M. Maggioni, G. Soardo, L.V. Valenti, A.L. Fracanzani, P. Dongiovanni